Crystal's MCW Coder Hub🧬ICD-10CM C67.8 - Malignant neoplasm of overlapping sites of bladder
Code Description
C67.8 - Malignant neoplasm of overlapping sites of bladder
This is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2026 edition of ICD-10-CM C67.8 became effective on October 1, 2025.
Code Hierarchy & Tree Structure
ICD-10-CM 2026
└── Chapter 2: Neoplasms (C00-D49)
└── C00-C96: Malignant neoplasms
└── C00-C75: Malignant neoplasms, stated or presumed to be primary
└── C64-C68: Malignant neoplasms of urinary tract
└── C67: Malignant neoplasm of bladder
├── C67.0: Malignant neoplasm of trigone of bladder
├── C67.1: Malignant neoplasm of dome of bladder
├── C67.2: Malignant neoplasm of lateral wall of bladder
├── C67.3: Malignant neoplasm of anterior wall of bladder
├── C67.4: Malignant neoplasm of posterior wall of bladder
├── C67.5: Malignant neoplasm of bladder neck
├── C67.6: Malignant neoplasm of ureteric orifice
├── C67.7: Malignant neoplasm of urachus
├── C67.8: Malignant neoplasm of overlapping sites of bladder ← THIS CODE
└── C67.9: Malignant neoplasm of bladder, unspecified
Official Coding Guidelines
Primary Malignant Neoplasms Overlapping Site Boundaries
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code ** (overlapping lesion)**, unless the combination is specifically indexed elsewhere.
For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
Functional Activity
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used to identify functional activity associated with any neoplasm.
Morphology/Histology
Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code.
Includes
The following conditions are included under C67.8:
- Adenocarcinoma, overlapping sites of bladder
- Cancer of the bladder, contiguous or overlap sites
- Malignant neoplasm, overlapping lesion of bladder
- Overlapping primary adenocarcinoma of bladder
- Overlapping primary squamous cell carcinoma of bladder
- Overlapping primary transitional cell carcinoma of bladder
- Squamous cell carcinoma, overlapping sites of bladder
- Transitional cell carcinoma, overlapping sites of bladder
Excludes
Excludes1 (Not Coded Here)
- C67.0-C67.7: When the specific site is documented and not overlapping
- C67.9: When the site is unspecified
- C68.8: Malignant neoplasm of overlapping sites of urinary organs (when involving organs beyond the bladder)
- D09.0: carcinoma in situ of bladder (non-invasive)
- D41.4: neoplasm of uncertain behavior of bladder
Excludes2 (Not Included Here)
- Secondary/metastatic bladder cancer: Code to C79.00 (Secondary malignant neoplasm of bladder) with primary site coded first
- History of bladder cancer: Use Z85.51 (Personal history of malignant neoplasm of bladder)
HCC (Hierarchical Condition Category) Information
CMS-HCC Model V28 (2026)
HCC Eligible: Yes
Model Year: 2026 CMS-HCC Version 28 (V28)
HCC Category: Solid Organ Malignancies
Risk Adjustment Factor (RAF) Impact:
- Bladder cancer diagnoses contribute to the HCC for Solid Malignancies
- Under V28, cancer HCCs require annual recapture for continued RAF credit
- The transition from V24 to V28 affects approximately 2000+ codes and may impact 22% of RAF scores
Documentation Requirements:
- Must be documented by a qualified healthcare provider
- Requires annual assessment for HCC capture in Medicare Advantage plans
- Active cancer treatment or monitoring should be documented
- History of cancer without active disease does not qualify for HCC credit
Important V28 Changes:
- CMS phased in V28 between 2024 and 2026 based on more recent FFS data
- Full implementation of CMS-HCC Version 28 occurred on January 1, 2026
- V28 includes 115 HCCs along with age-sex and demographic factors
MS-DRG (Medicare Severity Diagnosis Related Groups)
MS-DRG v43.0 (2026)
C67.8 is grouped within the following Diagnostic Related Groups:
| MS-DRG | Description | CC/MCC Status |
|---|---|---|
| 656 | Kidney and ureter procedures for neoplasm with MCC | With Major Complications/Comorbidities |
| 657 | Kidney and ureter procedures for neoplasm with CC | With Complications/Comorbidities |
| 658 | Kidney and ureter procedures for neoplasm without CC/MCC | Without CC/MCC |
| 686 | Kidney and urinary tract neoplasms with MCC | With Major Complications/Comorbidities |
| 687 | Kidney and urinary tract neoplasms with CC | With Complications/Comorbidities |
| 688 | Kidney and urinary tract neoplasms without CC/MCC | Without CC/MCC |
Note: DRG assignment depends on:
- Primary procedure performed
- Presence of complications/comorbidities (CC)
- Presence of major complications/comorbidities (MCC)
- Discharge status
Related CPT Codes for Bladder Cancer Procedures
Transurethral Bladder Tumor Procedures
| CPT Code | Description | wRVU (Facility) | wRVU (Non-Facility) | Assistant Payable | Global Days |
|---|---|---|---|---|---|
| 52204 | Cystourethroscopy with biopsy(s) | 3.80 | 10.64 | No | 0 |
| 52214 | Cystourethroscopy with fulguration | 4.55 | 21.80 | No | 0 |
| 52224 | Cystourethroscopy with fulguration/treatment of minor lesion(s) <0.5cm | 5.26 | 22.77 | No | 0 |
| 52234 | Cystourethroscopy with fulguration/resection of small bladder tumor(s) 0.5-2.0cm | 6.49 | N/A | Yes | 0 |
| 52235 | Cystourethroscopy with fulguration/resection of medium bladder tumor(s) 2.0-5.0cm | 7.62 | N/A | Yes | 0 |
| 52240 | Cystourethroscopy with fulguration/resection of large bladder tumor(s) | 10.30 | N/A | Yes | 0 |
Major Bladder Cancer Surgical Procedures
| CPT Code | Description | wRVU | Assistant Payable | Global Days |
|---|---|---|---|---|
| 51570 | Cystectomy, complete, with ureteroneocystostomy | 50.00+ | Yes | 90 |
| 51575 | Cystectomy, complete, with urethrectomy | 52.00+ | Yes | 90 |
| 51580 | Cystectomy, complete, with ileal conduit | 55.00+ | Yes | 90 |
| 51585 | Cystectomy, complete, with ureterosigmoidostomy | 55.00+ | Yes | 90 |
| 51590 | Cystectomy, complete, with continent urinary reservoir | 58.00+ | Yes | 90 |
| 51702 | Insertion of bladder catheter | 0.61 | No | 0 |
wRVU Notes:
- wRVU values based on 2026 Medicare Physician Fee Schedule
- Estimated reimbursement based on 2026 conversion factor ($33.40) and national average GPCI (1.0)
- Actual reimbursement varies by geographic location and payer
Assistant Surgeon Payable:
- “Yes” indicates Medicare allows assistant surgeon billing (modifiers -80, -82, or -AS)
- “No” indicates assistant surgeon is not separately payable
- Always verify with specific payer policies
Coding Examples
Example 1: Overlapping Bladder Tumor Resection
Clinical Scenario: Patient undergoes TURBT for malignant neoplasm involving both the trigone and lateral wall of the bladder (contiguous sites).
Codes:
- Primary Diagnosis: C67.8 - Malignant neoplasm of overlapping sites of bladder
- Procedure: 52235 - Cystourethroscopy with fulguration/resection of medium bladder tumor(s)
- Anesthesia: 00912 - Anesthesia for transurethral resection of bladder tumor
Rationale: Since the tumor involves two contiguous sites (trigone and lateral wall), C67.8 is appropriate rather than coding both C67.0 and C67.2 separately.
Example 2: Multiple Non-Contiguous Tumors
Clinical Scenario: Patient has separate tumors in the dome and bladder neck (non-contiguous sites).
Codes:
- Primary Diagnosis: C67.1 - Malignant neoplasm of dome of bladder
- Secondary Diagnosis: C67.5 - Malignant neoplasm of bladder neck
- Procedure: 52240 - Cystourethroscopy with fulguration/resection of large bladder tumor(s)
Rationale: For multiple neoplasms of the same site that are not contiguous, codes for each site should be assigned rather than using C67.8.
Example 3: Bladder Cancer with Metastasis
Clinical Scenario: Patient with primary bladder cancer with metastasis to regional lymph nodes.
Codes:
- Primary Diagnosis: C67.8 - Malignant neoplasm of overlapping sites of bladder
- Secondary Diagnosis: C77.5 - Malignant neoplasm of pelvic lymph nodes
- HCC Capture: Document active cancer treatment for RAF score
Rationale: Primary bladder cancer is coded first, followed by metastatic sites. Both codes may contribute to HCC risk adjustment.
Example 4: Post-Treatment Surveillance
Clinical Scenario: Patient with history of bladder cancer, currently disease-free, presenting for surveillance cystoscopy.
Codes:
- Primary Diagnosis: Z85.51 - Personal history of malignant neoplasm of bladder
- Procedure: 52000 - Cystourethroscopy
Rationale: When cancer is no longer active and patient is in surveillance, use history code Z85.51 rather than active cancer code C67.8. This does not qualify for HCC credit.
Documentation Requirements
Required Elements for C67.8
- Confirmation of malignancy (pathology report preferred)
- Site documentation showing involvement of multiple contiguous bladder sites
- Laterality if applicable (bladder is typically midline)
- Histology/type when available (transitional cell, adenocarcinoma, squamous cell)
- Stage/grade when documented (additional codes may be required)
- Treatment status (active treatment vs. surveillance vs. history)
HCC Documentation Best Practices
- Document active cancer clearly in assessment/plan
- Include treatment ongoing or cancer monitoring statements
- Avoid ambiguous terms like “history of” when cancer is active
- Recapture annually for Medicare Advantage patients
Common Coding Edits & NCCI Bundling
NCCI Procedure-to-Procedure Edits
| Column I Code | Column II Code | Modifier Allowed |
|---|---|---|
| 52234 | 52204 | No (biopsy bundled) |
| 52235 | 52214 | No (fulguration bundled) |
| 52240 | 52234 | No (small tumor bundled into large) |
| 52240 | 52235 | No (medium tumor bundled into large) |
| 51570 | 52240 | Yes, if separate session (modifier -59) |
Important Bundling Notes
- Biopsy (52204) is bundled into tumor resection codes (52234, 52235, 52240)
- Fulguration of bleeding vessels is bundled into TURBT procedures
- Multiple tumor resections of different sizes: code to the largest tumor only
- Separate and distinct procedures may require modifier -59 or -XS
Place of Service Considerations
| Setting | Typical CPT Codes | Payment Considerations |
|---|---|---|
| Office | 52000, 52204, 52214 | Higher non-facility wRVU |
| ASC | 52234, 52235, 52240 | APC 5374-5375, Status J1 |
| Hospital Outpatient | 52234, 52235, 52240 | APC payment, facility fees |
| Inpatient | 51570-51590 | MS-DRG 656-658, 686-688 |
APC Status Indicator J1: Significant procedure, multiple reduction applies
Quality Measures & Reporting
Relevant Quality Programs
- MIPS/QPP: Bladder cancer treatment may qualify for oncology measures
- Quality Payment Program: Document treatment planning and follow-up
- Cancer Registry: C67.8 is reportable to SEER and state cancer registries
SEER Reportability
C67.8 is classified as REPORTABLE for cancer registry purposes under FY2026 ICD-10-CM codes.
Code History
| Year | Effective Date | Status |
|---|---|---|
| 2016 | 2015-10-01 | New code (first year of non-draft ICD-10-CM) |
| 2017 | 2016-10-01 | No change |
| 2018 | 2017-10-01 | No change |
| 2019 | 2018-10-01 | No change |
| 2020 | 2019-10-01 | No change |
| 2021 | 2020-10-01 | No change |
| 2022 | 2021-10-01 | No change |
| 2023 | 2022-10-01 | No change |
| 2024 | 2023-10-01 | No change |
| 2025 | 2024-10-01 | No change |
| 2026 | 2025-10-01 | No change |
Crosswalk Information
ICD-9-CM Equivalent (Historical Reference)
| ICD-10-CM | ICD-9-CM | Description |
|---|---|---|
| C67.8 | 188.8 | Malignant neoplasm of other specified sites of bladder |
Note: ICD-9-CM codes are no longer valid for dates of service on or after October 1, 2015.
Clinical Pearls
-
Overlapping vs. Multiple: Use C67.8 only for contiguous sites. Non-contiguous tumors require separate site codes.
-
HCC Capture: Bladder cancer qualifies for HCC risk adjustment but requires annual documentation of active disease.
-
TURBT Coding: Select tumor resection code based on largest tumor size, not sum of all tumors.
-
Pathology Correlation: Always correlate ICD-10 code with pathology report when available for accuracy.
-
Metastatic Disease: If bladder cancer has metastasized, code primary C67.8 first, then secondary sites (C77.x, C78.x, C79.x).
-
In Situ vs. Invasive: Carcinoma in situ of bladder is coded D09.0, not C67.8.
Related Codes to Consider
Adjacent ICD-10-CM Codes
- C67.0 - Malignant neoplasm of trigone of bladder
- C67.1 - Malignant neoplasm of dome of bladder
- C67.2 - Malignant neoplasm of lateral wall of bladder
- C67.3 - Malignant neoplasm of anterior wall of bladder
- C67.4 - Malignant neoplasm of posterior wall of bladder
- C67.5 - Malignant neoplasm of bladder neck
- C67.6 - Malignant neoplasm of ureteric orifice
- C67.7 - Malignant neoplasm of urachus
- C67.9 - Malignant neoplasm of bladder, unspecified
- C68.8 - Malignant neoplasm of overlapping sites of urinary organs
- D09.0 - Carcinoma in situ of bladder
- D41.4 - Neoplasm of uncertain behavior of bladder
- C79.00 - Secondary malignant neoplasm of bladder
- Z85.51 - Personal history of malignant neoplasm of bladder
Related CPT Code Families
- 52000-52005 - Diagnostic cystourethroscopy
- 52204-52240 - Transurethral bladder tumor procedures
- 51570-51590 - Cystectomy procedures
- 00910-00912 - Anesthesia for transurethral procedures
References & Resources
- ICD-10-CM Official Guidelines for Coding and Reporting 2026
- CMS-HCC Model V28 Implementation Guide 2026
- Medicare Physician Fee Schedule 2026
- MS-DRG Definitions Manual v43.0
- NCCI Procedure-to-Procedure Edits 2026
- SEER Cancer Registry Reporting Guidelines
Last Updated: March 12, 2026 Code Version: ICD-10-CM 2026 Next Review: October 2026 (FY2027 updates)